Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376443 | 0.98 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL18538850 | 0.98 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL16373472 | 0.98 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL30928310 | 0.98 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL21031240 | 0.94 | MEN1 (0.53) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL9218143 | 0.93 | MEN1 (0.50) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL29262260 | 0.92 | MEN1 (0.70) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL30928306 | 0.92 | MEN1 (0.70) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL21031241 | 0.92 | MEN1 (0.56) | MEN1KMT2AMAPTALDH1A1ADORA1 | |
| SCHEMBL13203397 | 0.92 | MEN1 (0.51) | MEN1KMT2AMAPTALDH1A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222184-B1 | PREPARATION AND USE OF GAMMA-BUTYROLACTONES AS CROSS-LINKING AGENTS | DU PONT (US) | 2006-11-02 | — | — | EP | claimed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20240025927-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025927-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230389421-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230389421-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| EP-3935129-B1 | LIGANDS FOR NANO-SIZED MATERIALS | MERCK PATENT GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230363276-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230363276-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
| EP-1569633-A4 | CA IX-SPECIFIC INHIBITORS | INST VIROLOGY (SK) | 2008-03-05 | — | — | EP | disclosed |
| EP-1222184-B1 | PREPARATION AND USE OF GAMMA-BUTYROLACTONES AS CROSS-LINKING AGENTS | DU PONT (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060057068-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2006-03-16 | — | — | US | disclosed |
| EP-1569633-A2 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY (SK) | 2005-09-07 | — | — | EP | disclosed |
| US-6833460-B2 | Alternatives for isocyanates in coating compositions and application processes | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-20040146955-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2004-07-29 | — | — | US | disclosed |
| WO-2004048544-A2 | CA IX-SPECIFIC INHIBITORS | BAYER HEALTHCARE (US) | 2004-06-10 | — | — | WO | disclosed |
| US-6423850-B1 | CROSSLINKING COATINGS | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-4006149-A | COBALT CONTAINING | STUDIENGESELLSCHAFT KOHLE M.B.H. (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | MEN1 2568/4885KMT2A 1267/4885MAPT 1547/4885 |
| US-20060057068-A1 | CA IX-specific inhibitors | CA9, CA2, CA6 | MEN1 1315/4885KMT2A 1339/4885MAPT 4249/4885 |
| US-20230363276-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, ODC1 | MEN1 3319/4885KMT2A 3656/4885MAPT 758/4885 |
| US-20240025927-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, ODC1 | MEN1 2447/4885KMT2A 3397/4885MAPT 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.